PURE Bioscience, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2023 | — | $272.0K | $1.1M |
| FY2024 | — | $-2.9M | $349.0K |
| FY2025 | — | $-5.1M | $334.0K |
| FY2026 | $6.6M | $-6.4M | $569.0K |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2023 | — | $272.0K | $1.1M |
| FY2024 | — | $-2.9M | $349.0K |
| FY2025 | — | $-5.1M | $334.0K |
| FY2026 | $6.6M | $-6.4M | $569.0K |